Preferred Label : Lazertinib;
NCIt synonyms : N-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide;
NCIt definition : An orally available third-generation, selective inhibitor of certain forms of the
epidermal growth factor receptor (EGFR) with activating mutations, including the resistance
mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential
antineoplastic activity. Upon administration, lazertinib specifically and irreversibly
binds to and inhibits selective EGFR mutants, which prevents EGFR mutant-mediated
signaling and leads to cell death in EGFR mutant-expressing tumor cells. Lazertinib
may inhibit programmed cell death-1 ligand 1 (PD-L1) and inflammatory cytokines in
specific cancer cells harboring certain EGFR mutations. Compared to some other EGFR
inhibitors, lazertinib may have therapeutic benefits in tumors with T790M- or L858R-mediated
drug resistance. In addition, lazertinib penetrates the blood-brain barrier (BBB).
This agent shows minimal activity against wild-type EGFR (wtEGFR), and does not cause
dose-limiting toxicities, which occur during the use of non-selective EGFR inhibitors
and inhibit wtEGFR. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell
types, plays a key role in tumor cell proliferation and tumor vascularization.;
UNII : 4A2Y23XK11;
InChIKey : RRMJMHOQSALEJJ-UHFFFAOYSA-N;
CAS number : 1903008-80-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1903008-80-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : GNS-1480; YH-25448; YH 25448;
NCI Metathesaurus CUI : CL550797;
Origin ID : C148147;
UMLS CUI : C4724849;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_target
